Tudor Investment Corp ET AL Reduces Stock Holdings in Alignment Healthcare, Inc. (NASDAQ:ALHC)

Tudor Investment Corp ET AL decreased its holdings in shares of Alignment Healthcare, Inc. (NASDAQ:ALHC - Free Report) by 14.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 375,403 shares of the company's stock after selling 64,379 shares during the quarter. Tudor Investment Corp ET AL owned 0.20% of Alignment Healthcare worth $4,223,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ALHC. R Squared Ltd bought a new position in Alignment Healthcare in the 4th quarter valued at approximately $55,000. RiverPark Advisors LLC bought a new position in shares of Alignment Healthcare in the 4th quarter valued at $106,000. Tower Research Capital LLC TRC boosted its holdings in shares of Alignment Healthcare by 146.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company's stock valued at $119,000 after acquiring an additional 6,286 shares in the last quarter. Ballentine Partners LLC bought a new stake in Alignment Healthcare during the 4th quarter worth $121,000. Finally, Aigen Investment Management LP acquired a new position in Alignment Healthcare in the 4th quarter worth about $129,000. Institutional investors own 86.19% of the company's stock.

Alignment Healthcare Trading Down 0.3 %

NASDAQ ALHC traded down $0.05 during trading hours on Monday, hitting $15.48. 2,990,640 shares of the company's stock were exchanged, compared to its average volume of 1,817,456. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of -20.10 and a beta of 1.32. The stock has a 50-day simple moving average of $17.27 and a 200 day simple moving average of $14.31. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. Alignment Healthcare, Inc. has a 1-year low of $6.37 and a 1-year high of $21.06.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.07. Alignment Healthcare had a negative net margin of 5.84% and a negative return on equity of 108.69%. The company had revenue of $926.93 million during the quarter, compared to the consensus estimate of $889.83 million. During the same quarter last year, the firm posted ($0.25) EPS. The company's quarterly revenue was up 47.5% on a year-over-year basis. On average, equities analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO John E. Kao sold 90,000 shares of the business's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $14.23, for a total transaction of $1,280,700.00. Following the completion of the sale, the chief executive officer now directly owns 2,183,100 shares of the company's stock, valued at $31,065,513. The trade was a 3.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andreas P. Wagner sold 14,878 shares of the firm's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $14.38, for a total transaction of $213,945.64. Following the completion of the transaction, the insider now directly owns 200,885 shares in the company, valued at approximately $2,888,726.30. The trade was a 6.90 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,181,855 shares of company stock worth $35,166,057. Corporate insiders own 6.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Stephens restated an "overweight" rating and set a $17.00 price target on shares of Alignment Healthcare in a report on Monday, February 24th. Piper Sandler raised their price target on shares of Alignment Healthcare from $14.00 to $21.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. UBS Group boosted their price objective on shares of Alignment Healthcare from $16.00 to $17.00 and gave the stock a "neutral" rating in a research note on Friday. William Blair reaffirmed an "outperform" rating on shares of Alignment Healthcare in a research report on Friday, February 28th. Finally, Robert W. Baird upped their price target on Alignment Healthcare from $17.00 to $22.00 and gave the company an "outperform" rating in a research report on Tuesday, April 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $17.17.

Alignment Healthcare Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.